Status:
COMPLETED
A Study of IBI3032 in Chinese Healthy Subjects
Lead Sponsor:
Innovent Biologics Technology Limited (Shanghai R&D Center)
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
This is a randomized, double-blind, placebo-controlled Phase I clinical study evaluating the safety, tolerability, PK and food effect of a single dose of IBI3032 in healthy participants. This is a sin...
Eligibility Criteria
Inclusion
- Healthy male or females, as determined by medical history
- Have safety laboratory results within normal reference ranges
Exclusion
- Have known allergies toIBI3032， glucagon-like peptide-1 (GLP-1) analogs, related compounds
- Abnormal electrocardiogram (ECG) at screening
- Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.
Key Trial Info
Start Date :
August 29 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 7 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07134127
Start Date
August 29 2025
End Date
October 7 2025
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Frist Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230000